- Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma. 2018 Academic Article GET IT
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Biology of Blood and Marrow Transplantation.
Times cited: 1
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*.
Leukemia and Lymphoma.
Times cited: 5
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
British Journal of Haematology.
Times cited: 27
Myelodysplastic syndromes: What do hospitalists need to know?.
Journal of Hospital Medicine.
Times cited: 15